95 related articles for article (PubMed ID: 20692828)
1. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
Perrone F; Jocollè G; Pennati M; Deraco M; Baratti D; Brich S; Orsenigo M; Tarantino E; De Marco C; Bertan C; Cabras A; Bertulli R; Pierotti MA; Zaffaroni N; Pilotti S
Eur J Cancer; 2010 Oct; 46(15):2837-48. PubMed ID: 20692828
[TBL] [Abstract][Full Text] [Related]
2. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.
Tamborini E; Casieri P; Miselli F; Orsenigo M; Negri T; Piacenza C; Stacchiotti S; Gronchi A; Pastorino U; Pierotti MA; Pilotti S
J Pathol; 2007 Jun; 212(2):227-35. PubMed ID: 17471466
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
4. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809
[TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
Barbieri F; Würth R; Favoni RE; Pattarozzi A; Gatti M; Ratto A; Ferrari A; Bajetto A; Florio T
Biochem Pharmacol; 2011 Nov; 82(10):1467-77. PubMed ID: 21787763
[TBL] [Abstract][Full Text] [Related]
6. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.
Perrone F; Da Riva L; Orsenigo M; Losa M; Jocollè G; Millefanti C; Pastore E; Gronchi A; Pierotti MA; Pilotti S
Neuro Oncol; 2009 Dec; 11(6):725-36. PubMed ID: 19246520
[TBL] [Abstract][Full Text] [Related]
7. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.
Kobayashi M; Takeuchi T; Ohtsuki Y
Anticancer Res; 2008; 28(1A):197-208. PubMed ID: 18383846
[TBL] [Abstract][Full Text] [Related]
8. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.
Lagonigro MS; Tamborini E; Negri T; Staurengo S; Dagrada GP; Miselli F; Gabanti E; Greco A; Casali PG; Carbone A; Pierotti MA; Pilotti S
J Pathol; 2006 Apr; 208(5):615-23. PubMed ID: 16470538
[TBL] [Abstract][Full Text] [Related]
9. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
[TBL] [Abstract][Full Text] [Related]
10. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
Conde E; Angulo B; Tang M; Morente M; Torres-Lanzas J; Lopez-Encuentra A; Lopez-Rios F; Sanchez-Cespedes M
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):710-7. PubMed ID: 16467080
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.
Signoroni S; Frattini M; Negri T; Pastore E; Tamborini E; Casieri P; Orsenigo M; Da Riva L; Radice P; Sala P; Gronchi A; Bertario L; Pierotti MA; Pilotti S
Clin Cancer Res; 2007 Sep; 13(17):5034-40. PubMed ID: 17785554
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma.
Enomoto Y; Kasai T; Takeda M; Takano M; Morita K; Kadota E; Iizuka N; Maruyama H; Haratake J; Kojima Y; Ikeda N; Inatsugi N; Nonomura A
J Clin Pathol; 2012 Jun; 65(6):522-7. PubMed ID: 22412050
[TBL] [Abstract][Full Text] [Related]
13. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
Gaafar R; Bahnassy A; Abdelsalam I; Kamel MM; Helal A; Abdel-Hamid A; Eldin NA; Mokhtar N
Lung Cancer; 2010 Oct; 70(1):43-50. PubMed ID: 20347505
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
Cesario A; Catassi A; Festi L; Imperatori A; Pericelli A; Galetta D; Margaritora S; Porziella V; Cardaci V; Granone P; Dominioni L; Russo P
Clin Cancer Res; 2005 Mar; 11(5):2026-37. PubMed ID: 15756029
[TBL] [Abstract][Full Text] [Related]
17. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
18. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
Dewaele B; Floris G; Finalet-Ferreiro J; Fletcher CD; Coindre JM; Guillou L; Hogendoorn PC; Wozniak A; Vanspauwen V; Schöffski P; Marynen P; Vandenberghe P; Sciot R; Debiec-Rychter M
Cancer Res; 2010 Sep; 70(18):7304-14. PubMed ID: 20685895
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Coley HM; Shotton CF; Ajose-Adeogun A; Modjtahedi H; Thomas H
Biochem Pharmacol; 2006 Oct; 72(8):941-8. PubMed ID: 16934227
[TBL] [Abstract][Full Text] [Related]
20. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors.
Welin S; Fjällskog ML; Saras J; Eriksson B; Janson ET
Neuroendocrinology; 2006; 84(1):42-8. PubMed ID: 17047316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
